2025
Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.
Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, Kaviani R, Hosseini K, Pasebani Y, Khederlou H, Rafati A, Mohammadi Z, Jamalkhani S, Talasaz A, Firouzi A, Ariannejad H, Alemzadeh-Ansari M, Ahmadi-Renani S, Maadani M, Farrashi M, Bakhshandeh H, Piazza G, Krumholz H, Mehran R, Lip G, Bikdeli B. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention 2025, 21: 82-92. PMID: 39773831, PMCID: PMC11684328, DOI: 10.4244/eij-d-24-00527.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionLeft ventricular thrombusLeft ventricular thrombus resolutionRandomised clinical trialsPooled analysisVentricular thrombusTreatment of left ventricular thrombusTwo-dimensional transthoracic echocardiographyMyocardial infarctionDirect oral anticoagulantsImaging core laboratoryWarfarin-based anticoagulationMeta-analysis of randomised trialsTransthoracic echocardiographyOpen-labelOral anticoagulantsBleeding eventsAdult patientsDOACsCore laboratoryWarfarinClinical trialsRandomised trialsPatientsBleeding
2024
Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Left Atrial Appendage Occlusion
Reinhardt S, Gibson D, Hsu J, Kapadia S, Yeh R, Price M, Piccini J, Nair D, Christen T, Allocco D, Freeman J. Anticoagulation Alone vs Anticoagulation Plus Aspirin or DAPT Following Left Atrial Appendage Occlusion. Journal Of The American College Of Cardiology 2024, 84: 889-900. PMID: 39197978, DOI: 10.1016/j.jacc.2024.05.067.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionRate of adverse eventsAdverse eventsLAA closure deviceAppendage occlusionAntithrombotic strategiesP2Y<sub>12</sub> inhibitorsDays of follow-upMultivariable Cox proportional hazards regressionClosure deviceRisk of adverse eventsCox proportional hazards regressionWatchman FLX deviceDual antiplatelet therapyDevice-related thrombusProportional hazards regressionStroke/transient ischemic attackAntithrombotic regimensFLX deviceAntiplatelet therapyDOACsGroup patientsFollow-upMultivariate analysisHazards regression
2023
S1589 Risks and Benefits of DOACS vs Warfarin in Patients With AF and Liver Disease - A Systematic Review and Meta-Analysis
Khalid A, Mautong H, Hasnol H, Njei B. S1589 Risks and Benefits of DOACS vs Warfarin in Patients With AF and Liver Disease - A Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2023, 118: s1201-s1202. DOI: 10.14309/01.ajg.0000955996.51119.b8.Peer-Reviewed Original Research
2022
Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.Peer-Reviewed Original ResearchPrevention of venous thromboembolismVenous thromboembolismOral anticoagulantsPediatric hematologistsClinically relevant nonmajor bleeding eventsTreatment of acute venous thromboembolismSecondary prevention of venous thromboembolismUS Food and Drug Administration approvalFood and Drug Administration approvalRecurrent thrombosis rateDirect oral anticoagulantsAcute venous thromboembolismNonmajor bleeding eventsPediatric venous thromboembolismDrug Administration approvalFemales aged >Prescribed DOACsDOAC useBleeding complicationsBleeding eventsMenstrual bleedingAnticoagulation regimenDOACsAdministration approvalOff-label
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply